Myocyte enhancing factor-2A in Alzheimer's disease: Genetic analysis and association with MEF2A-polymorphisms

Neuroscience Letters

Volumn 411, Issue 1, 2007, Pages 47-51

  González, Pelayo ^a   Álvarez, Victoria ^a   Menéndez, Manuel ^a   Lahoz, Carlos H ^a   Martínez, Carmen ^b   Corao, Ana I ^a   Calatayud, María T ^a   Peña, Joaquín ^a   García Castro, Mónica ^a   Coto, Eliecer ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

Author keywords

DNA polymorphisms; Genetic association; Late onset Alzheimer's disease; Myocyte enhancing factor 2A

Indexed keywords

APOLIPOPROTEIN E; LEUCINE; POLYGLUTAMINE;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MUSCLE CELL; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; TRANSCRIPTION INITIATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEUCINE; MADS DOMAIN PROTEINS; MALE; MIDDLE AGED; MYOGENIC REGULATORY FACTORS; ODDS RATIO; PEPTIDES; POLYMORPHISM, GENETIC; PROLINE;

EID: 33751020835     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.09.055     Document Type: Article

References (42)

1. Alvarez V., Alvarez R., Lahoz C.H., Martinez C., Pena J., Guisasola L.M., Salas-Puig J., Moris G., Uria D., Menes B.B., Ribacoba R., Vidal J.A., Sanchez J.M., and Coto E. Frequency of the APOE-4 allele in Alzheimer's disease and its variation with age in Asturias (Spain). Med. Clin. (Barc) 113 (1999) 441-443
2. Barsyte-Lovejoy D., Galanis A., Clancy A., and Sharrocks A.D. ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif. Biochem. J. 381 (2004) 693-699
3. Bennett D.A., Schneider J.A., and Wilson R.S. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J. Neurol. Neurosurg. Psychiatry 76 (2005) 1194-1199
4. Bertram L., and Tanzi R.E. The genetic epidemiology of neurodegenerative diseases. J. Clin. Invest. 115 (2005) 1449-1457
5. Bhagavatula M.R., Fan C., Shen G.Q., Cassano J., Plow E.F., Topol E.J., and Wang Q. Trancription factor MEF2A mutations in patients with coronary artery disease. Hum. Mol. Genet. 13 (2004) 3181-3188
6. Burton T.R., Dibrov A., Kashour T., and Amara F.M. Anti-apoptotic wild-type Alzheimer amyloid precursor protein signalling involves the p38 mitogen-activated protein kinase/MEF2 pathway. Mol. Brain Res. 108 (2002) 102-120
7. Gaudilliere B., Shi Y., and Bonni A. RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival. J. Biol. Chem. 277 (2002) 46442-46446
8. Giambarella U., Yamatsuji T., Okamoto T., Matsui T., Ikezu T., Murayama Y., Levine M.A., Katz A., Gautam N., and Nishimoto I I. G protein betagamma complex-mediated apoptosis by familial Alzheimer's disease mutatnt of APP. EMBO J. 16 (1997) 4897-4907
9. González P., García-Castro M., Reguero J.R., Batalla A., Ordonez A.G., Palop R.L., Lozano I., Montes M., Alvarez V., and Coto E. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. J. Med. Genet. 43 (2006) 167-169
10. Heidenreich K.A., and Linseman D.A. Myocyte enhancer factor-2 (MEF2) transcription factors in neuronal differentiation and survival. Mol. Neurobiol. 29 (2004) 1-11
11. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
12. Hof P.R., and Morrison J.H. The aging brain: morphonuclear senescence of cortical circuits. Trends. Neurosci. 27 (2004) 607-613
13. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004) 347-360
14. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., and Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 (1987) 733-736
15. Lambert J.C., Mann D., and Richard F. Is there a relation between APOE expression and brain amyloid load in Alzheimers disease?. J. Neurol. Neurosurg. Psychiatry 76 (2005) 928-933
16. Leifer D., Krainc D., Yu Y.T., McDermott J., Breitbart R.E., Heng J., Neve R.L., Kosofsky B., Nadal-Ginard B., and Lipton S.A. MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1546-1550
17. Leifer D., Golden J., and Kowall N.W. Myocyte-specific enhancer binding factor 2C expression in human brain development. Neuroscience 63 (1994) 1067-1079
18. Li M., Linseman D.A., Allen M.P., Meintzer M.K., Wang X., Laessig T., Wierman M.E., and Heidenreich K.A. Myocyte enhancer factor 2A and 2D undergo phosphorylation and caspase-mediated degradation during apoptosis of rat cerebellar granule neurons. J. Neurosci. 21 (2001) 6544-6552
19. Lin X., Shah S., and Bulleit R.F. The expression of MEF2 genes is implicated in CNS neuronal differentiation. Brain Res. Mol. Brain Res. 42 (1996) 307-316
20. Lyons G.E., Micales B.K., Schwarz J., Martin J.F., and Olson E.N. Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J. Neurosci. 15 (1995) 5727-5738
21. McDermott J.C., Cardoso M.C., Yu Y.T., Andres V., Leifer D., Krainc D., Lipton S.A., and Nadal-Ginard B. hMEF2C gene encodes skeletal muscle and brain-specific transcription factors. Mol. Cell. Biol. 13 (1993) 2564-2577
22. McKinsey T.A., Zhang C.L., and Olson E.N. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends. Bichem. Sci. 27 (2002) 40-47
23. Mao Z., Bonni A., Xia F., Nadal-Vicens M., and Greenberg M.E. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286 (1999) 785-790
24. Mayeux R., Sano M., Chen J., Tatemichi T., and Stern Y. Risk of dementia in first-degree relatives of patients with Alzheimer's disease and related disorders. Arch. Neurol. 48 (1991) 269-273
25. Nalbantoglu J., Gilfix B.M., and Bertrand P. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann. Neurol. 36 (1994) 889-895
26. Nishimura I., Uetsuki T., Dani S.U., Ohsawa Y., Saito I., Okamura H., Uchiyama Y., and Yoshikawa K. Degeneration in vivo of rat hippocampal neurons by wild-type Alzheimer amyloid precursor protein overexpressed by adenovirus-mediated gene transfer. J. Neurosci. 18 (1998) 2387-2398
27. Okamoto T., Takeda S., Murayama Y., Ogata E., and Nishimoto I. Ligand-dependent G protein coupling function of amyloid transmembrane precursor. J. Biol. Chem. 270 (1995) 4205-4208
28. Okamoto S., Li Z., Ju C., Scholzke M.N., Mathews E., Cui J., Salvesen G.S., Bossy-Wetzel E., and Lipton S.A. Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3974-3979
29. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., and Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1977-1981
30. Scott W.K., Hauser E.R., Schmechel D., Welsh-Bohmer K.A., Small G.W., Roses A.D., Saunders A.M., Gilbert J.R., Vance J.M., Haines J.L., and Pericak-Vance M.A. Ordered subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. Am. J. Hum. Genet. 73 (2003) 1041-1051
31. Shore P., and Sharrocks A.D. The MADS-box family of transcription factors. Eur. J. Biochem. 229 (1995) 1-13
32. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high activity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1977-1981
33. Tanzi R.E. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. J. Clin. Invest. 104 (1999) 1175-1179
34. Tanzi R.E., and Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 32 (2001) 181-184
35. Verkhratsky A., Mattson M.P., and Toescu E.C. Aging in the mind. Trends Neurosci. 27 (2004) 577-578
36. Wenham P.R., Price W.H., and Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 337 (1991) 1158-1159
37. Wu Z., Guo H., Chow N., Sallstrom J., Bell R.D., Deane R., Brooks A.I., Kanagala S., Rubio A., Sagare A., Liu D., Li F., Armstrong D., Gasiewicz T., Zidovetzki R., Song X., Hofman F., and Zlokovic B.V. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 11 (2005) 959-965
38. Xu X., Yang D., Wyss-Coray T., Yan J., Gan L., Sun Y., and Mucke L. Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 7547-7552
39. Yang S.H., Galanis A., and Sharrocks A.D. Targeting of p38 mitogen-activated kinases to MEF2 transcription factors. Moll. Cell. Biol. 19 (1999) 4028-4038
40. Ye S., Huang Y., and Mullendorff K. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 18700-18705
41. Yu Y.T., Breitbart R.E., Smoot L.B., Lee Y., Mahdavi V., and Nadal-Ginard B. Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. Genes Dev. 6 (1992) 1783-1798
42. Zubenko G.S., Stiffler S., and Stabler S. Association of the apolipoprotein E epsilon 4 allele with clinical subtypes of autopsy-confirmed Alzheimer's disease. Am. J. Med. Genet. 54 (1994) 199-205